Yoko Mano
Taisho Pharmaceutical Co.
6 Papers
5 Citations
Yoko Mano is an academic researcher from Taisho Pharmaceutical Co.. The author has contributed to research in topics: Pharmacokinetics & Organic anion transporter 1. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Usefulness of Rat Skin as a Substitute for Human Skin in the in Vitro Skin Permeation Study
Hiroyuki Takeuchi,Yoko Mano,Shuichi Terasaka,Takanobu Sakurai,Atsushi Furuya,Hidetoshi Urano,Kenji Sugibayashi +6 more
TL;DR: In vitro permeation studies using SD rat skin would be especially useful for evaluating differences in the skin permeability of the three model drugs as well as for predicting humanSkin permeability.
94
Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates
TL;DR: The present PBPK model incorporating the in vivo Ki values was found to be useful for quantitative prediction of clinical DDIs and for estimation of the Fg values for CYP3A4 substrates for which intravenous data were not available.
23
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials
Y. Takeuchi,Yukihiro Chino,Masafumi Kawanishi,Megumi Nakanishi,H. Watase,Yoko Mano,Yuri Sato,Saeko Uchida,Yoshiya Tanaka +8 more
TL;DR: Ozoralizumab (OZR), a tumor necrosis factor alpha (TNFα) inhibitor, is a NANOBODY® compound that binds to TNFα and human serum albumin this article .
17
In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Yukihiro Chino,Masatoshi Hasegawa,Yoshiki Fukasawa,Yoko Mano,Kagumi Bando,Atsunori Miyata,Yasuhiro Nakai,Hiromi Endo,Junichi Yamaguchi +8 more
TL;DR: Based on the therapeutic plasma concentration of the drug, clinically relevant drug interactions are unlikely to occur between luseogliflozin and coadministered drugs mediated by CYPs and/or transporters.
3
Drug-drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H3 receptor antagonist.
Shuichi Terasaka,Kenji Hachiuma,Yoko Mano,Koichi Onishi,Iwao Kitajima,Izumi Nishino,Hiromi Endo +6 more
TL;DR: In this article, the authors evaluated the in vitro drug-drug interaction (DDI) potential of TS-091, a histamine H3 receptor antagonist/inverse agonist, mediated by cytochrome P450 (CYP) and transporters.
2